7
1, Burgemeester E. Demunterlaan 1090 Brussels, Belgium Tel. +32 2 479 93 60 [email protected] www.camel-ids.com November 2017
1,Burgemeester E.Demunterlaan1090Brussels,[email protected] November2017
Camel-IDS 2
Companyhighlights
Capitalefficient,leanandmean
Preclinicalpipelinewithtwoprogramsleveragingtechnologystrengths
Clinicalstageradionuclidetherapycompanyinoncology
• Focusoncamelidsingledomainantibodies(sdAb)labeledwithradioisotopes• LeadprograminPhaseI,twoearlypre-clinicalprograms
1
2 • PhaseIcompletebyYE2017• PhaseIIpreparatoryworkfullyongoing,studystartinQ22019subjecttofunding
3 • CAM-alpha– First-in-humantrialanticipatedin2020• CAM-beta– First-in-humantrialanticipatedin2021
4 • Companycreatedin2014• EUR3mequityraisedcomplementedwithEUR2minnon-dilutivefunding
CAM-H2,anewtreatmentoptioninHER2-positivecancers
Camel-IDS 3
Managementteam
JensDeVosChiefOperatingOfficer
• Co-FounderCamel-IDS• PhDinBio-engineeringsciences(VUB)• EMBA(Vlerick BusinessSchool)
RuthDevenynsChiefExecutiveOfficer
• Ogeda CFOuntilthecompany’sacquisitionbyAstellas inMay2017• >20yearsexperienceinthefinancialsectorincludingatKBC,Degroof
Petercam andKorys• JoinedCamel-IDSinSeptember2017• MasterinAppliedEconomics(GhentUniversity)
TonyLahoutteChiefMedicalOfficer
• Co-FounderCamel-IDS• HeadofNuclearMedicineatUZBrussel• Directorofthehumanresearchandprotectionprogram(UZBrussel)• Researchfocusontheclinicaltranslationofsingledomainantibodiesas
diagnosticsandtherapeutics• MDPhDaccreditedinnuclearmedicine(VUB)
Camel-IDS 4
Managementteam
NickDevoogdtDiscovery
• Co-FounderCamel-IDS• FullProfessorinAppliedBiologicalSciences(VUB)• Specializedindeveloping novelsingledomainantibodiesinvarious
diseasesettings,for imagingand therapeutic applications• Inventor of12patents,65publications and book chapter,H-factor26
MatthiasD’HuyvetterChiefScientificOfficer
• Co-founderCamel-IDS• ResearchProfessor(VUB)• PhDinMedicalSciences(VUB)• EMBA(AntwerpManagementSchool)
GeertRaesIntellectualProperty&Legal
• Co-FounderCamel-IDS• >15yearsexperienceasstaffscientistandvalorizationmanagerat
VIB-VUB• PhDinAppliedBiologicalSciences(VUB)
Camel-IDS 5
Singledomainantibodieslabeledwithradioisotopes
5
sdAbRadioisotope
Linker
Camel-IDSconcept Mechanismofaction
LinkerConjugatestheradioisotopetosdAbs
RadioisotopeKillscancercellsthroughDNAbreaks
Potency:b- vs.a emittersHalf-lifeinsyncwithsdAbhalf-life
Availability
StableinbloodTrappedinsidecancercellsNore-uptakeinkidney
sdAbTargetsthecancercells
Specificbinding,fastontargetDeeptumorpenetrationRapidrenalclearance
Fastandspecificdeliveryofradioisotopestocancerlesionsthroughoutthebody,
whilepreservinghealthytissue
Camel-IDS 6
Developmentplan
2017
CAM-H2
CAM-alpha
H1 H2
Today
PhaseIbPhaseIa
PhaseIPre-clinical
TargettohaveleadprogramPhaseIIcompletebyYE2022…
…with2earlierprogramsPhaseIcomplete
CAM-beta PhaseI
2018
H1 H2
2019
H1 H2
2020
H1 H2
2021
H1 H22022
H1 H2
PhaseII
Leadoptimization
Pre-clinicalLeadgeneration&optimization
PIb/IIenabling
Camel-IDS
Camel-IDStime-line
Q42014 Camel-IDSincorporationbyscientificfounders
Innoviris grantforfirstproductCAM-H2
VUBbecomesshareholderthroughcontributionIP
SeriesAFinancing
Seedfinancingby3BA’sandFournier-Majoie Foundation
Innoviris grantforCAM-alphaandCAM-betadevelopment
Q22015
Q42014
Q22015
2018
Q42015Q12017 PhaseICAM-H2inhealthysubjects
Q22017 Additionalseedfinancingexistingshareholders
Q42017 PhaseICAM-H2inCancerpatients
